Pulmatrix Inc (PULM)

[StocktraderDK]

PULM is a long term hold. Cost of Lung cancer treatments cost £2.4B a Year and How Covid has increased the number of people who will have respiratory diseases.

Any type of lung cancer is devastating. According to cancer research UK, the annual cost of lung cancer is over £2B. And in the US, the cost of a single patient treatment is between $10,000 - $15000.

How does COVID-19 affect the overall respiratory system?

COVID-19 can affect the respiratory system in a variety of ways and across a spectrum of levels of disease severity, depending on a person’s immune system, age and comorbidities. Symptoms can range from mild, such as cough, shortness of breath and fevers, to critical disease, including respiratory failure, shock and multi-organ system failure.

Respiratory issues are growing faster than ever due to Covid. The long term effects of Covid include respiratory symptoms and conditions such as chronic cough, shortness of breath, lung inflammation and fibrosis, and pulmonary vascular disease. With more and more people recovering from Covid, there are more people who are going to be at severe risk to respiratory problems. This makes PULM a huge player for the future, as there is going to be a huge demand for respiratory treatment. This is where PULM comes in and will be able to deliver effective treatments to treat respiratory problems in the future.This indicates how PULM is a long term investment and not a quick swing trade due to the “public offering”.

From UCHealth it states:

“Can COVID-19 cause permanent lung damage? For those who have underlying health conditions, what does long-term lung damage mean for them?

Yes, it's possible and perhaps likely that people with chronic lung injury are at higher risk of long-term complications. We don't know, but data from severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS) suggests that as many as 50% of people who have had COVID-19 may have some lung damage. “

Let’s do some Maths. Let’s say 50% of people who have had Covid have respiratory problems in the future. In total there have been 111M cases with 62.4M people who have recovered fully and 2.45M deaths worldwide. Just in the US there has been 28M cases. If 50% contract respiratory problems in the future this leads to an additional 14M people on top of the current 25M people in the US who already have respiratory problems. That gives a grand total of 39M people who will/have respiratory problems. This indicates the huge market PULM has to target in the future and how PULM will be able to grow revenues significantly.

More info is posted on r/PULM

Also make sure you check out:

https://www.reddit.com/r/pennystocks/comments/lnj1nh/indepth_dd_on_pulm_biopharma_pennystock/?utm_source=share&utm_medium=ios_app&utm_name=iossmf